Corporate Profile

Onconetix, Inc. (Nasdaq: ONCO) (formerly Blue Water Biotech, Inc. (BWV)) is a commercial stage biotechnology company focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The Company currently has Entadfi®, an FDA approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix®, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. For more information, visit www.onconetix.com.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

SEC Filings

Report of unscheduled material events or corporate event

8-K

Report of unscheduled material events or corporate event

8-K

Form of prospectus disclosing information facts events covered in both forms 424B1 424B3